bpc-157 safety human case reports adverse effects Preclinical evaluation of body protective compound-157, a potential drug for treating various wounds BPC 157 in Australia: Benefits,
Description
Shingrix Shingles vaccine will be available to patients over 65 years and First Nations People over 50 The federal health minister recently announced that from the 1st of November 2023, the recombinant zoster vaccine (RZV, sold as Shingrix) will be made available under the National Immunisation Program (NIP) for free to patients over 65 years old, First Nations People over 50 and immunocompromised people 18 years and over at high risk of herpes zoster infection
[DOI] [PMC free article] [PubMed] [Google Scholar] 76
Coding pernicious anemia based on clinical suspicion alone invites audit scrutiny
You've got 100
